Abstracts Archive - Page 127 of 2425 - ACR Meeting Abstracts

Abstract Number: 1667 • ACR Convergence 2024
Correlates of Physical Activity (PA) in Persons Undergoing Total Knee Arthroplasty (TKA): Does Pain Matter?
Elena Losina¹, Jamie Collins¹, Clare Safran-Norton¹, Mike Paskewicz¹, Faith Selzer², Sonia Pavlesen³, Kelly Frier¹, Jon Dhani¹, Darya Lee¹, Ella Macdonald³, Alexa Streicher³, Linda Ehrlich-Jones⁴, Neil Segal⁵, Christine Pellegrini⁶, Elizabeth Wellsandt⁷, Rowland Chang⁸ and Jeffrey Katz¹, and KArAT Team, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Amesbury, MA, ³University of Buffalo, Buffalo, NY, ⁴Shirley Ryan Ability Lab, Chicago, IL, ⁵University of Kansas, Kansas City, KS, ⁶University of South Carolina, Columbia, SC, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Northwestern University Division of Rheumatology, Chicago, IL
Background/Purpose: Low PA in persons with symptomatic knee osteoarthritis (OA) has often been attributed to pain. Evolving data suggest that TKA recipients do not increase…
Abstract Number: 1684 • ACR Convergence 2024
Autoantibodies to Transcription Factor a Mitochondria Are Associated with Damage Accrual, Malignancy Risk and Mortality in SLE
Eduardo Gomez¹, Daniel Goldman², Merlin Paz³, Michelle Petri² and Felipe Andrade⁴, ¹The Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³Johns Hopkins Medicine, Baltimore, MD, ⁴The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: We recently identified autoantibodies in SLE that target transcription factor A mitochondrial (TFAM), a critical protein in mitochondrial DNA transcription and packaging1. These autoantibodies…
Abstract Number: 1734 • ACR Convergence 2024
Safety and Efficacy Data from a Phase I Trial of Umbilical Lining-Derived Stem Cells (ULSC) in Adult Dermatomyositis/Polymyositis
Michael R Bubb`¹, Eileen Handberg¹, Rafael Gonzalez², Blas Betancourt¹, J. Nicole Bostick¹, Sarah Long¹, Keith March¹ and Carl Pepine¹, ¹University of Florida, Gainesville, FL, ²Restem, LLC, Corona, CA
Background/Purpose: Mesenchymal stem/stromal cells are self-renewing, multi-potent stromal cells which act as modulators of immune responses. Umbilical cord-derived mesenchymal stromal cells, a classification of cells…
Abstract Number: 1789 • ACR Convergence 2024
Multi-omic Profiling Identifies Pathogenic Pro-inflammatory Human Monocytes/Macrophages in Systemic Lupus Erythematosus
Lais Osmani¹, Min Shin², Sang Jin Lee³, Helen Cai⁴, Won Jae Seong², Hyoungsu Kim², Jongjin Yoo², Angela Mirabella², William Bracamonte², Mario Felix⁵, Jong Gyun Ahn², Hong-Jai Park², Juan Young⁶, Junghee Shin², Serhan Unlu⁷, Noelle Yoo², Edward Doherty², Jiaye Chen², Chenxi Li², Gabriela Sanchez-Zuno², Caroline Valdez⁴, Thuy Tran⁸, Mei Dong², Sang Kim², Christine Ko⁹, Sungyong You¹⁰, Jose Gomez¹¹, Richard Bucala¹² and Insoo Kang², ¹Yale, New Haven, CT, ²Yale University School of Medicine, Internal Medicine (Rheumatology, Allergy & Immunology), New Haven, CT, ³Division of Rheumatology, Kyungpook National University Hospital, Dae gu, Republic of Korea, ⁴Yale University School of Medicine, New Haven, CT, ⁵Yale, Hamden, CT, ⁶Yale University School of Medicine, Psychiatry, New Haven, CT, ⁷Cleveland Clinic, Internal Medicine, Cleveland, OH, ⁸Yale University School of Medicine, Internal Medicine (Medical Oncology), New Haven, CT, ⁹Yale University School of Medicine, Dermatology and Pathology, New Haven, CT, ¹⁰Cedars-Sinai Medical Center, Surgery and Computational Biomedicine, Los Angeles, CA, ¹¹Yale University School of Medicine, Internal Medicine (Pulmonary, Critical Care & Sleep), New Haven, CT, ¹²Yale University School of Medicine, Internal Medicine (Rheumatology, Allergy & Immunology) and Pathology, New Haven, CT
Background/Purpose: Systemic lupus erythematosus (SLE or lupus) is a clinically heterogeneous autoimmune disease, in which emerging evidence implicates the innate immune system, particularly monocytes and…
Abstract Number: 1773 • ACR Convergence 2024
Divergent Genetic Architecture in Boys and Girls with NEMO-deleted Exon 5 Autoinflammatory Syndrome (NEMO-NDAS) Implies Role for Wildtype Effector Cells
Adriana Almeida de Jesus¹, Kip Friend², Bin Lin³, Eric Karlins⁴, Colton McNinch⁴, Sara Alehashemi⁵, Keith Kauffman⁶, FARZANA BHUYAN³, Taylor Newbolt⁶, Andrea Bohrer⁷, Andre Rastegar³, Sophia Park³, Dana Kahle³, Jacob Mitchell³, Amanda Chen³, Sofia Torreggiani⁸, Kader Cetin Gedik⁹, Katsiaryna Uss², Amer Khojah¹⁰, Eveline Wu¹¹, Christiaan Scott¹², Timothy Ronan Leahy¹³, Emma MacDermott¹⁴, Orla Killeen¹⁵, Thaschawee Arkachaisri¹⁶, Brian Nolan¹⁷, Zoran Gucev¹⁸, Kathryn Cook¹⁹, Vafa Mammadova²⁰, Gulnara Nasrullayeva²⁰, Mariana Correia Marques²¹, Abigail Bosk²², Seza Ozen²³, Scott Canna²⁴, Maude Tusseau²⁵, Emilie Chopin²⁶, Guilaine Boursier²⁷, Veronique Hentgen²⁸, Ines Elhani²⁹, Mario Sestan³⁰, Marija Jelusic³¹, Danielle Fink³², Douglas Kuhns³², Clifton Dalgard³³, Alexandre Belot³⁴, Timothy Moran¹¹, Katherine Meyer-Barber⁷, Andrew Oler⁴, Daniel Barber⁶ and Raphaela Goldbach-Mansky³⁵, ¹NIAID, NIH, Silver Spring, MD, ²Translational Autoinflammatory Diseases section (TADS), LCIM, NIAID, NIH, Bethesda, MD, ³TADS, NIAID, NIH, Bethesda, MD, ⁴BCBB, NIAID, NIH, Bethesda, MD, ⁵NIH/NIAID/TADS, Potomac, MD, ⁶T Lymphocyte Biology Section, LPD, NIAID, NIH, Bethesda, MD, ⁷Inflammation and Innate Immunity Unit, LCIM, NIAID, NIH, Bethesda, MD, ⁸University Of Maryland Baltimore, Baltimore, MD, ⁹Translational Autoinflammatory Diseases section (TADS), LCIM, NIAID, NIH, Pittsburgh, PA, ¹⁰Umm Al-Qura University, Makkah, Saudi Arabia, ¹¹University of North Carolina School of Medicine, Chapel Hill, NC, ¹²University of Cape Town, Cape Town, South Africa, ¹³Children’s Health Ireland (CHI) at Crumlin, Dublin, Ireland, ¹⁴CHI Crumlin, Dublin, Dublin, Ireland, ¹⁵Children's Health Ireland, Dublin, Ireland, ¹⁶KK Women's and Children's Hospital, SingHealth, Singapore, Singapore, ¹⁷Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, IL, ¹⁸University Children's Hospital, Skopje, Macedonia, ¹⁹Akron Children's Hospital, Akron, OH, ²⁰Azerbaijan Medical University, Baku, Azerbaijan, ²¹National Institutes of Health, Bethesda, MD, ²²Children's National Hospital, Bethesda, DC, ²³Department of Pediatrics, Hacettepe University, Ankara, Turkey, ²⁴Children's Hospital of Philadelphia, Philadelphia, PA, ²⁵RAISE, Hospices Civils de Lyon, Lyon, France, ²⁶Hospices Civils de Lyon, Lyon, France, ²⁷University of Montpellier, Montpellier, ²⁸Laboratoire de Génétique des Maladies Rares et Autoinflammatoires, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, CEREMAIA, CHU de Montpellier, Univ Montpellier, Montpellier, France, Le Chesnay, France, ²⁹Department of Internal Medicine, Caen University Hospital, Caen, France, Caen, France, ³⁰University of Zagreb School of Medicine University Hospital Centre Zagreb, Zagreb, Croatia, ³¹University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ³²Collaborative Clinical Research Branch, NIAID, NIH, Bethesda, MD, Bethesda, MD, ³³The American Genome Center, Department of Anatomy, Physiology & Genetics, Uniformed Services University, Bethesda, MD, ³⁴Hospices Civils de Lyon, Collonges au mont d'or, France, ³⁵Translational Autoinflammatory Diseases section (TADS), LCIM, NIAID, NIH, Potomac, MD
Background/Purpose: Splice-site variants in X-linked IKBKG cause NEMO-deleted exon5 autoinflammatory syndrome (NEMO-NDAS); a pseudogene (IKBKGP1) complicates genetic diagnosis. NEMO-NDAS is four times more common in…
Abstract Number: 1757 • ACR Convergence 2024
Bimekizumab Treatment Resulted in Improvements in MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis: 52-Week Results and Post Hoc Analyses from Two Phase 3 Studies
Walter Maksymowych¹, Sofia Ramiro², Denis Poddubnyy³, Xenofon Baraliakos⁴, Robert Lambert¹, Ute Massow⁵, Thomas Vaux⁶, Chetan Prajapati⁶, Alexander Marten⁵, Natasha de Peyrecave⁷ and Mikkel Ostergaard⁸, ¹University of Alberta, Edmonton, AB, Canada, ²Leiden University Medical Center, Bunde, Netherlands, ³Charite-Universitatsmedizin Berlin, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Brussels, Belgium, ⁸Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark
Background/Purpose: The impact of bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL-17A, on structural lesions in patients (pts)…
Abstract Number: 1817 • ACR Convergence 2024
Activated Macrophages Mediate Loss of Dermal White Adipose Tissue in Fibrotic Skin
Chanhyuk Park¹, Helen Jarnagin², Asmaa Mohamed³, Yina Huang³, Michael Whitfield⁴ and Patricia Pioli¹, ¹Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Dartmouth College, Lebanon, NH, ³Dartmouth, Lebanon, ⁴Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Autoimmune systemic sclerosis (SSc) is characterized by inflammation, vasculopathy, and dermal and internal organ fibrosis. A widely-reported but poorly understood aspect of SSc skin…
Abstract Number: 1736 • ACR Convergence 2024
Effectiveness and Safety of Tofacitinib vs. Calcineurin Inhibitor in Interstitial Lung Disease Secondary to Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis: A Multi-Center Cohort Study with Propensity Score-Based Inverse Probability of Treatment Weighting
Wanlong Wu¹, Bingpeng Guo², Wenjia Sun³, Dan Chen⁴, Wenwen Xu⁵, Zhiwei Chen⁵, Yakai Fu⁵, Yan Ye⁵, Xia Lyu⁶, Zhixin Xue⁵, Kaiwen Wang⁵, Jiangfeng Zhao⁷, Chunhua Ye⁵, Min Dai⁵, Wei Fan⁵, Jia Li⁵, Xiaodong Wang⁵, Yu Xue⁸, Weiguo Wan⁸, Li Sun⁴, Huaxiang Wu⁹, Qun Luo², Qian Han², Qiong Fu¹ and Shuang Ye¹, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²State Key Laboratory of Respiratory Disease, National Clinical Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China (People's Republic), ³The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China (People's Republic), ⁴The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China (People's Republic), ⁵Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁶Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China (People's Republic), ⁷Department of Rheumatology, Jiading Branch, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁸Department of Rheumatology, Huashan Hospital, Fudan University, shanghai, China (People's Republic), ⁹Department of Rheumatology, The Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China (People's Republic)
Background/Purpose: The current management of anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5+DM) is challenging and largely empirical rather than evidence-based. Small-sized proof-of-concept trial and case series…
Abstract Number: 1554 • ACR Convergence 2024
Belimumab Increases SLE Responder Index-4 Response Rates versus Placebo in Early Active Systemic Lupus Erythematosus: A Large Integrated Analysis of Belimumab Trials
Karen Costenbader¹, Joan Merrill², Marta Mosca³, Holly Quasny⁴, Christine Henning⁵, Steven Bloom⁶, Julia Harris⁶, Ciara O’Shea⁷, Tatsuya Atsumi⁸ and Ronald van Vollenhoven⁹, ¹Brigham and Women’s Hospital, Division of Rheumatology, Inflammation and Immunity, Harvard Medical School, Boston, MA, ²Oklahoma Medical Research Foundation, Arthritis & Clinical Immunology Program, Oklahoma City, OK, ³University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ⁴GSK, Clinical Sciences, Durham, NC, ⁵GSK, Global Medical Affairs, Durham, NC, ⁶GSK, Immunology Biostatistics, Brentford, United Kingdom, ⁷GSK, Rheumatology, Global Medical Affairs, Dublin, Ireland, ⁸Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ⁹Amsterdam Rheumatology and Immunology Center and Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands

Background/Purpose: There are benefits of early treatment for autoimmune diseases; however, data are not available for patients (pts) with SLE as there is no definition…
Abstract Number: 1571 • ACR Convergence 2024
Growth Differentiation Factor 15 Is a Serum Biomarker and Pathogenic Factor of Progressive Fibrosis in Systemic Sclerosis
Vishal Kakkar¹, Sunhwa Kim², Yingtao Bi³, Christopher Wasson¹, Stefano Di Donato⁴, Rebecca Ross⁵, Marco Di Battista⁶, Enrico De Lorenzis⁷, Thierry Sornasse² and Francesco Del Galdo¹, ¹University of Leeds, Leeds, United Kingdom, ²AbbVie, South San Francisco, CA, ³Abbvie, Worcester, MA, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ⁵Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Pisa, United Kingdom, ⁷Catholic University of the Sacred Heart, Roma, Rome, Italy
Background/Purpose: In systemic sclerosis (SSc), interstitial lung disease (ILD) remains the leading cause of mortality. A decline in forced vital capacity (FVC) is considered a…
Abstract Number: 1788 • ACR Convergence 2024
Memory B Cell Activation and Dysregulation in Systemic Lupus Erythematosus
Shady Younis¹, Salvinaz Moutusy², Shaghayegh Jahanbani², Xiaohao Wu², Marlayna Harris², Mahesh Pandit³, Laura van Dam⁴, orr Sharpe⁵, Paul Utz¹ and William Robinson⁶, ¹Stanford University, Stanford, CA, ²Stanford University School of Medicine, Stanford, ³Stanford University School of Medicine, Stanofrd, ⁴Stanford, Palo Alto, CA, ⁵Department of Immunology and Rheumatology, Stanford University, Stanford, CA, ⁶Division of Immunology and Rheumatology, Stanford University, and VA Palo Alto Health Care System, Stanford, CA
Background/Purpose: B cell dysregulation and production of autoantibodies against autoantigens are hallmarks of Systemic lupus erythematosus (SLE). In healthy adults (HC), B cells with autoreactive…
Abstract Number: 1519 • ACR Convergence 2024
Incidence, Risk Factors, and Outcomes of Severe Lymphopenia in Systemic Lupus Erythematosus
Chunhui Chen¹, Emily Wu², Huong Do³ and Kyriakos Kirou³, ¹New York Presbyterian Queens, Flushing, NY, ²Hospital for Special Surgery, Rochester, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: Lymphopenia is common in patients with systemic lupus erythematosus (SLE), occurring in 75-90% of cases over the disease course. It can result from SLE…
Abstract Number: 1818 • ACR Convergence 2024
Distribution and Morphological Changes of Adventitial Fibroblasts in Healthy and Scleroderma Skin
Banafsheh Nazari¹, Tracy Tabib², Christina Morse³ and Robert Lafyatis², ¹UPMC-Mercy, Pittsburgh, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh
Background/Purpose: Our previous single-cell RNA-sequencing study identified two major fibroblast subpopulations in healthy skin biopsies: SFRP2/DPP4 and FMO1/LSP1 fibroblasts¹. Additionally, we discovered that adventitial fibroblasts…
Abstract Number: 1708 • ACR Convergence 2024
Unveiling the Uterine-Joint Axis: Dysbiosis and Subclinical Uterine Inflammation in Female Axial Spondyloarthritis Pathogenesis
Daniele Mauro¹, Matteo Vecellio², Anne-Sophie Bergot³, Eva Schmid⁴, Giulio Forte⁵, Alessia Stingo⁶, Alessia Salzillo⁵, Aldo Pastore⁷, Paolo Aretini⁷, Francesca Di Lorenzo⁷, Antonio ciancio⁵, Ilenia Pantano⁵, Gabriele Saccone⁸, Fulvio Zullo⁹, carlo Maurizio Montecucco¹⁰, Aroldo Rizzo¹¹, Georg Schett¹², Ranjeny Thomas¹³, Mario Zaiss¹⁴ and Francesco Ciccia¹⁵, ¹University of Campania, Italy, Naples, Naples, Italy, ²Fondazione Pisana per la Scienza ONLUS, Pisa, Italy, ³Frazer Institute, University of Queensland, Brisbane, Australia, ⁴Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Rheumatology and Immunology, Erlangen, Erlangen, Germany, ⁵University of Campania L. Vanvitelli, Naples, Italy, ⁶University of Campania L. Vanvitelli, Nasples, Italy, ⁷Fondazione Pisana per la Scienza ONLUS, Giuliano Terme, Italy, ⁸University Federico II of Naples, Naples, Italy, ⁹University of Catanzaro, Catanzaro, Italy, ¹⁰Unit of Rheumatology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy, ¹¹Azienda Ospedaliera Ospedali riuniti Villa Sofia Cervello,, Palermo, Italy, ¹²Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ¹³University of Queensland, Brisbane, Australia, ¹⁴Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universittsklinikum Erlangen, Erlangen, Germany; 2 Deutsches Zentrum für Immuntherapie (DZI), Erlangen, Germany, ¹⁵Università degli studi della Campania Luigi Vanvitelli, Naples, Italy
Background/Purpose: Numerous studies exploring gender differences in axial spondyloarthritis (AxSpA) have noted that women exhibit distinct disease manifestations. Yet, a definitive pathophysiological distinction of these diverse…
Abstract Number: 1578 • ACR Convergence 2024
Association of Systemic Sclerosis and Other Systemic Autoimmune Disease Diagnosis with Increasing Anti-RNA Polymerase III Antibodies
Warren Balaja¹, Mashood Badshah² and Megan Krause³, ¹University of Kansas Medical Center, Kansas City, KS, ²The University of Kansas Medical Center, Kansas City, KS, ³University of Kansas, Kansas City, KS
Background/Purpose: Anti-RNA polymerase III antibody (ARA) is a disease-specific antibody important for the identification and stratification of varying phenotypes of systemic sclerosis (SSc). Previous studies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].